Citation

  • Authors: Kim DH. et al.
  • Year: 2022
  • Journal: Phytother Res
  • Applications: in vitro / siRNA / INTERFERin
  • Cell type: LNCaP
    Description: Human prostate carcinoma cells

Method

LNCaP were seeded onto 6 well (1.5x10^5/well) and then were transfected with negativ control, B-catenin siRNA for 24hours by using INTERFERin transfection reagent (Polyplus-transfection) according to manufacturer's protocol.

Abstract

The goal of the current study is to assess the antitumor mechanism by the combination (7:3) of Angelica gigas and Torilis japonica (AT) that was found most effective through screening against prostate-specific antigen (PSA) in LNCaP prostate cancer cells. Here, AT reduced the viability and the number of colonies in androgen-dependent LNCaP cells more than in androgen independent PC3 and DU145 cells. Also, AT induced G1 phase arrest, cleaved PARP and caspase 3, activated p27 and decreased the expression of Cyclin D1, Cyclin E, cdk2 in LNCaP cells. Furthermore, AT decreased the expression of PSA and androgen receptor (AR) at mRNA and protein levels in LNCaP cells. Interestingly, AT attenuated the expression of AR, PSA and Wnt-3a and the stability of AR and PSA in LNCaP cells. Furthermore, AT reversed dihydrotestosterone (DHT)-induced upregulation of AR and PSA in LnCaP cells. Notably, AT disrupted the protein-protein interaction, nuclear translocation and fluorescent expression of β-catenin and AR in LNCaP cells. Consistently, β-catenin depletion enhanced the decreased expression of AR in AT treated LNCaP cells. Taken together, our findings highlight evidence that AT suppresses the proliferation of LNCaP cells via G1 arrest and inhibition of β-catenin and AR as a potential anticancer agent.

Go to